Education
About Us
Working with TipRanks
Follow Us
Evolus Inc (EOLS)
NASDAQ:EOLS
EOLS Stock Chart & Stats
$5.74
-$0.47(-4.38%)
At close: 4:00 PM EST
$5.74
-$0.47(-4.38%)
Day’s Range― - ―
52-Week Range$5.61 - $17.12
Previous CloseN/A
Volume344.54K
Average Volume (3M)865.13K
Market Cap
$372.07M
Enterprise Value$508.79M
Total Cash (Recent Filing)$43.52M
Total Debt (Recent Filing)$154.89M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Mar 11, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding64,819,786
10 Day Avg. Volume942,889
30 Day Avg. Volume865,131
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)123.99
Price to Sales (P/S)2.57
P/FCF Ratio-35.16
Enterprise Value/Market Cap1.37
Enterprise Value/Revenue1.78
Enterprise Value/Gross Profit2.70
Enterprise Value/Ebitda-17.36
Forecast
1Y Price Target
$19.25Price Target Upside235.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market ShareAnalysts expect the company to gain market share versus competitors through effective product differentiation and commercial execution, positioning it to outperform when demand improves.
Product LaunchesCommercial rollout of a new injectable filler (Evolysse) and additional filler introductions should diversify revenue streams and provide fresh growth drivers beyond the toxin franchise.
Profitability OutlookManagement expects to reach sustainable annual profitability in the near term and projects non-GAAP operating income of $5 million to $7 million in the fourth quarter, supporting confidence in the financial trajectory.
Bears Say
Guidance OverhangManagement's 2028 revenue target of $700 million acts as an overhang, increasing investor uncertainty about the achievability of long-term goals.
Long-term Guidance CutManagement reduced long-term revenue expectations significantly, lowering prior growth ambitions and prompting reassessment of future performance assumptions.
Macro Consumer DemandContinuing macroeconomic pressures and weak consumer sentiment are suppressing demand for discretionary aesthetic treatments, restricting growth for toxins and fillers.
Evolus News
EOLS FAQ
What was Evolus Inc’s price range in the past 12 months?
Evolus Inc lowest stock price was $5.61 and its highest was $17.12 in the past 12 months.
What is Evolus Inc’s market cap?
Evolus Inc’s market cap is $372.07M.
When is Evolus Inc’s upcoming earnings report date?
Evolus Inc’s upcoming earnings report date is Mar 11, 2026 which is in 59 days.
How were Evolus Inc’s earnings last quarter?
Evolus Inc released its earnings results on Nov 05, 2025. The company reported -$0.132 earnings per share for the quarter, beating the consensus estimate of -$0.163 by $0.031.
Is Evolus Inc overvalued?
According to Wall Street analysts Evolus Inc’s price is currently Undervalued.
Does Evolus Inc pay dividends?
Evolus Inc does not currently pay dividends.
What is Evolus Inc’s EPS estimate?
Evolus Inc’s EPS estimate is 0.04.
How many shares outstanding does Evolus Inc have?
Evolus Inc has 64,819,786 shares outstanding.
What happened to Evolus Inc’s price movement after its last earnings report?
Evolus Inc reported an EPS of -$0.132 in its last earnings report, beating expectations of -$0.163. Following the earnings report the stock price went up 5.433%.
Which hedge fund is a major shareholder of Evolus Inc?
Currently, no hedge funds are holding shares in EOLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evolus Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.25 (235.37% Upside)
$19.25 (235.37% Upside)
Blogger Sentiment
Bullish
EOLS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 8.8%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.78%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.62%
Trailing 12-Months
Company Description
Evolus Inc
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
EOLS Company Deck
EOLS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects strong growth in consumer engagement, successful product launches, and international expansion, despite facing macroeconomic challenges and tariff uncertainties. Evolus demonstrates resilience and strategic adaptation, positioning for continued growth.View all EOLS earnings summariesEOLS Stock 12 Month Forecast
Average Price Target
$19.25
▲(235.37% Upside)
Technical Analysis
Emergent Biosolutions
―
Rockwell Med
―
Organogenesis Holdings
―
Aquestive Therapeutics
―
Journey Medical Corp
―
Ownership Overview
3.26% Insiders
9.22% Mutual Funds
43.63% Other Institutional Investors
32.23% Public Companies and
Individual Investors